


**AMENDMENT TO CLAIMS:**

Claims 1-26 (canceled)

27. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a separated and purified, or synthetic procyanidin oligomer.
28. (currently amended) The pharmaceutical composition of claim 27, wherein the procyanidin oligomer is at least one procyanidin oligomer 2-12.
29. (currently amended) The pharmaceutical composition of claim 27, wherein the procyanidin oligomer is at least one procyanidin oligomer 2-5.
30. (currently amended) The pharmaceutical composition of claim 27, wherein the procyanidin oligomer is at least one procyanidin oligomer 4-12.
31. (currently amended) The pharmaceutical composition of claim 27, wherein the procyanidin oligomer is B-2 procyanidin.
32. (currently amended) The pharmaceutical composition of claim 27, wherein the procyanidin oligomer is B-5 procyanidin.
33. (currently amended) The pharmaceutical composition of claim 27, wherein the procyanidin oligomer has the following formula:




wherein n is 2 to 5.

34. (previously presented) The pharmaceutical composition of claim 27, adapted for administration by injection.

(W:\DOCS\NJPC\1010\100US3\00001474.DOC)

35. (currently amended) The pharmaceutical composition of claim 34, wherein the procyanidin oligomer is at least one procyanidin oligomer 2-12.
36. (currently amended) The pharmaceutical composition of claim 34, wherein the procyanidin oligomer is at least one procyanidin oligomer 2-5.
37. (currently amended) The pharmaceutical composition of claim 34, wherein the procyanidin oligomer is at least one procyanidin oligomer 4-12.
38. (currently amended) The pharmaceutical composition of claim 34, wherein the procyanidin oligomer is B-2 procyanidin.
39. (currently amended) The pharmaceutical composition of claim 34, wherein procyanidin oligomer is B-5 procyanidin.
40. (currently amended) The pharmaceutical composition of claim 34, wherein the procyanidin oligomer has the following formula:




wherein n is 2 to 5.

41. (previously presented) The pharmaceutical composition of claim 27, adapted for nasal administration.
42. (currently amended) The pharmaceutical composition of claim 41, wherein the procyanidin oligomer is at least one procyanidin oligomer 2-12.
43. (currently amended) The pharmaceutical composition of claim 41, wherein the procyanidin oligomer is at least one procyanidin oligomer 2-5.
44. (currently amended) The pharmaceutical composition of claim 41, wherein the procyanidin oligomer is at least one procyanidin oligomer 4-12.

{W:\DOCS\NJPC\101001\00us3\00001474.DOC}

45. (currently amended) The pharmaceutical composition of claim 41, wherein the procyanidin oligomer is B-2 procyanidin.
46. (currently amended) The pharmaceutical composition of claim 41, wherein procyanidin oligomer is B-5 procyanidin.
47. (currently amended) The pharmaceutical composition of claim 41, wherein the procyanidin oligomer has the following formula:




wherein n is 2 to 5.

48. (previously presented) The pharmaceutical composition of claim 27, adapted for rectal administration.
49. (currently amended) The pharmaceutical composition of claim 48 wherein the procyanidin oligomer is at least one procyanidin oligomer 2-12.
50. (currently amended) The pharmaceutical composition of claim 48 wherein the procyanidin oligomer is at least one procyanidin oligomer 2-5.
51. (currently amended) The pharmaceutical composition of claim 48 wherein the procyanidin oligomer is at least one procyanidin oligomer 4-12.
52. (currently amended) The pharmaceutical composition of claim 48 wherein the procyanidin oligomer is B-2 procyanidin.
53. (currently amended) The pharmaceutical composition of claim 48 wherein procyanidin oligomer is B-5 procyanidin.

{W:\DOCS\NJP\1010\0100us3\00001474.DOC}

54. (currently amended) The pharmaceutical composition of claim 48 wherein the procyanidin oligomer has the following formula:




wherein n is 2 to 5.

55. (previously presented) The pharmaceutical composition of claim 27, adapted for vaginal administration.
56. (currently amended) The pharmaceutical composition of claim 55, wherein the procyanidin oligomer is at least one procyanidin oligomer 2-12.
57. (currently amended) The pharmaceutical composition of claim 55, wherein the procyanidin oligomer is at least one procyanidin oligomer 2-5.
58. (currently amended) The pharmaceutical composition of claim 55, wherein the procyanidin oligomer is at least one procyanidin oligomer 4-12.
59. (currently amended) The pharmaceutical composition of claim 55, wherein the procyanidin oligomer is B-2 procyanidin.
60. (currently amended) The pharmaceutical composition of claim 55, wherein procyanidin oligomer is B-5 procyanidin.

{W:\DOC\S\NJPCU\010\0100us3\00001474.DOC}

61. (currently amended) The pharmaceutical composition of claim 55, wherein the procyanidin oligomer has the following formula:




wherein  $n$  is 2 to 5.

62. (currently amended) The pharmaceutical composition of claim 1 27, further comprising an additional anti-tumor, anti-cancer and/or anti-neoplastic agent.
63. (previously presented) The pharmaceutical composition of claim 34, further comprising an additional anti-tumor, anti-cancer and/or anti-neoplastic agent.
64. (previously presented) The pharmaceutical composition of claim 41, further comprising an additional anti-tumor, anti-cancer and/or anti-neoplastic agent.
65. (previously presented) The pharmaceutical composition of claim 48, further comprising an additional anti-tumor, anti-cancer and/or anti-neoplastic agent.
66. (previously presented) The pharmaceutical composition of claim 55, further comprising an additional anti-tumor, anti-cancer and/or anti-neoplastic agent.
67. (new) The pharmaceutical composition of claim 27, wherein the procyanidin oligomer is synthetic.
68. (new) The pharmaceutical composition of claim 67, wherein the procyanidin oligomer is at least one procyanidin oligomer 2-12.
69. (new) The pharmaceutical composition of claim 67, wherein the procyanidin oligomer is at least one procyanidin oligomer 2-5.
70. (new) The pharmaceutical composition of claim 67, wherein the procyanidin oligomer is at least one procyanidin oligomer 4-12.

(W:\DOCS\NJPC\1010\0100us3\00001474.DOC)

71. (new) The pharmaceutical composition of claim 67, wherein the procyanidin oligomer is B-2 procyanidin.
72. (new) The pharmaceutical composition of claim 67, wherein the procyanidin oligomer is B-5 procyanidin.
73. (new) The pharmaceutical composition of claim 67, wherein the procyanidin oligomer has the following formula:



wherein n is 2 to 5.

74. (new) The pharmaceutical composition of claim 67, adapted for administration by injection.
75. (new) The pharmaceutical composition of claim 67, adapted for nasal administration.
76. (new) The pharmaceutical composition of claim 67, adapted for rectal administration.
77. (new) The pharmaceutical composition of claim 67, adapted for vaginal administration.
78. (new) The pharmaceutical composition of claim 67, further comprising an additional anti-tumor, anti-cancer and/or anti-neoplastic agent.

{W:\DOCS\NJP\1010\100US3\00001474.DOC}

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**